In the recent three years, CJCR has been making tremendous progresses in a steady way. Its IF has grown from 0.182 (2011), to 0.448 (2012), to 0.932 (2013) and now 1.935 (2014) (Figure 1). The journal developed from a quarterly publication to a bi-monthly journal in 2013ever since it was transferred to AME Publishing Company to be in charge of its publication. Journal of Thoracic Disease, another journal published by AME Publishing Company, also makes its debut of receiving the first IF: 1.783.
Figure 1 Variation of CJCR’s impact factor during the last four years.
On behalf of our Honorary Editor-in-Chief, Yan Sun, Editor-in-Chief, Yang Ke and Executive Editor-in-Chief, JiafuJi, we would like to take this chance to express our heartfelt thanks to our outstanding editorial board members, reviewers, authors and readers for their support and fine contributions. In the future, with the join efforts, we are determined to bring our journal to a novel level in this academic arena of cancer research and make it a robust platform for more doctors and investigators worldwide.
CJCR is ABSTRACTED/INDEXED IN:
Science Citation Index Expanded (SCIE), PubMed Central (PMC), PubMed, Scoups, EMBASE, Chemical Abstracts Service (CAS), Google Scholar, CSA, Academic One File, Chinese Science Citation Database, Gale, Journal Citation Reports/Science Edition, OCLC, SCImago, Summon by Serial Solutions.
